1.71
+0.34(+24.82%)
Currency In USD
| Previous Close | 1.37 |
| Open | 2.04 |
| Day High | 2.43 |
| Day Low | 1.67 |
| 52-Week High | 3.7 |
| 52-Week Low | 0.66 |
| Volume | 114.26M |
| Average Volume | 2.98M |
| Market Cap | 197.01M |
| PE | -19 |
| EPS | -0.09 |
| Moving Average 50 Days | 0.93 |
| Moving Average 200 Days | 1.62 |
| Change | 0.34 |
If you invested $1000 in Coherus BioSciences, Inc. (CHRS) 10 years ago, it would be worth $120.59 as of December 04, 2024 at a share price of $1.71. Whereas If you bought $1000 worth of Coherus BioSciences, Inc. (CHRS) shares 5 years ago, it would be worth $93.44 as of December 04, 2024 at a share price of $1.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor - - Proceeds to fund development of key combination programs with LOQTORZI
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
GlobeNewswire Inc.
Nov 27, 2024 9:01 PM GMT
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Deve
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire Inc.
Nov 06, 2024 9:01 PM GMT
– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and packaging production resuming at third-party contract manufacturing organization – – LOQTORZI® launch progressing